Our publications - Institut Roche

Phosphoantigens and butyrophilin 3A1 induce similar intracellular activation signaling in human TCRVγ9+ γδ T lymphocytes. Immunology letters, 161(1), 133–137.

Decaup, E., Duault, C., Bezombes, C., Poupot, M., Savina, A., Olive, D., & Fournié, J. J. (2014).

https://doi.org/10.1016/j.imlet.2014.05.011

High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia, 28(12), 2367–2375.

Rossille, D., Gressier, M., Damotte, D., Maucort-Boulch, D., Pangault, C., Semana, G., Le Gouill, S., Haioun, C., Tarte, K., Lamy, T., Milpied, N., Fest, T., Groupe Ouest-Est des Leucémies et Autres Maladies du Sang, & Groupe Ouest-Est des Leucémies et Autres Maladies du Sang (2014).

https://doi.org/10.1038/leu.2014.137

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings. BMC cancer, 14, 178.

Bieche, I., Vacher, S., Vallerand, D., Richon, S., Hatem, R., De Plater, L., Dahmani, A., Némati, F., Angevin, E., Marangoni, E., Roman-Roman, S., Decaudin, D., & Dangles-Marie, V. (2014).

https://doi.org/10.1186/1471-2407-14-178

Impact of a second opinion using expression and molecular analysis of FOXL2 for sex cord-stromal tumors. A study of the GINECO group & the TMRO network. Gynecologic oncology, 132(1), 181–187.

Maillet, D., Goulvent, T., Rimokh, R., Vacher-Lavenu, M. C., Pautier, P., Alexandre, J., Pujade-Laurraine, E., Devouassoux-Shisheboran, M., Treilleux, I., Ray-Coquard, I., & Savina, A. (2014).

https://doi.org/10.1016/j.ygyno.2013.10.013

Cell growth in aggregates determines gene expression, proliferation, survival, chemoresistance, and sensitivity to immune effectors in follicular lymphoma. The American journal of pathology, 184(1), 282–295.

Gravelle, P., Jean, C., Familiades, J., Decaup, E., Blanc, A., Bezombes-Cagnac, C., Laurent, C., Savina, A., Fournié, J. J., & Laurent, G. (2014).

https://doi.org/10.1016/j.ajpath.2013.09.018

Mitochondrial oxidative stress is the Achille’s heel of melanoma cells resistant to Braf-mutant inhibitor. Oncotarget, 4(11), 1986–1998.

Corazao-Rozas, P., Guerreschi, P., Jendoubi, M., André, F., Jonneaux, A., Scalbert, C., Garçon, G., Malet-Martino, M., Balayssac, S., Rocchi, S., Savina, A., Formstecher, P., Mortier, L., Kluza, J., & Marchetti, P. (2013).

https://doi.org/10.18632/oncotarget.1420

Prediction of Shrinkage of Individual Parameters Using the Bayesian Information Matrix in Non-Linear Mixed Effect Models with Evaluation in Pharmacokinetics. Pharm Res 30, 2355–2367 (2013).

Combes, F.P., Retout, S., Frey, N. et al.

https://doi.org/10.1007/s11095-013-1079-3

AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med 19, 1288–1296 (2013).

Canaud, G., Bienaimé, F., Viau, A. et al.

https://doi.org/10.1038/nm.3313

Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model. Blood cancer journal, 3(8), e131.

Decaup, E., Jean, C., Laurent, C., Gravelle, P., Fruchon, S., Capilla, F., Marrot, A., Al Saati, T., Frenois, F. X., Laurent, G., Klein, C., Varoqueaux, N., Savina, A., Fournié, J. J., & Bezombes, C. (2013).

https://doi.org/10.1038/bcj.2013.32